Eurofins’ sales up almost 50% in the first half year of 2006
Brussels/ Nantes, August 3, 2006
Eurofins’ sales up almost 50% in the first half year of 2006
Brussels/ Nantes, August 3, 2006
Over the period from January 1 until June 30, 2006, Eurofins achieved sales of € 150.9 million, which corresponds to a growth of 49% compared with HY1/ 2005 (€ 101.0 million). Therewith, Eurofins is well in line with its objective to reach a turnover of € 300 million for the full year 2006.
In the second quarter of 2006, Eurofins reached sales of € 80.7 million representing a growth of 44% compared with Q2/ 2005 (€ 56.1 million).
Besides the organic growth, a major part of the sales increase is due to various acquisitions and outsourcing agreements carried out during the past 12 months, such as GAB Biotechnologie (Germany), LEM, Pharmacontrol, Optimed (all France), Focus Bio-Inova (France/USA), AvTech (USA), Steins (Denmark), Direct Laboratories and Agriseach (both UK).
The full results of the first half-year of 2006 will be published on August 29, 2006.
For further information please visit www.eurofins.com or contact:
Investor Relations |
|
|---|---|
|
Dr. Stefan Eckhoff (International Investor Relations) Tél : +32-2-766 16 20 E-mail : ir@eurofins.com |
Hugues Vaussy (Investor Relations France) Tél: +33-(0)2-51 83 21 00 E-mail: irFrance@eurofins.com |
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.
With over 3,500 staff in more than 70 laboratories across 17 countries, Eurofins offers a portfolio of over 10,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to provide its customers with high quality services, accurate results in time and, if requested, expert advice by our highly qualified staff.
The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both, its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international player in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on Euronext in the Paris (ISIN FR0000038259) and Frankfurt ( WKN 910251) Stock Exchanges ( Reuters EUFI.LN, Bloomberg ERSC FP, ESF, EUFI.DE).Important disclaimer:
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.